文献速递心脑血管急症消化、代谢与肾脏急症

甘油三酯降低型LPL变异与LDL-C降低型LDLR变异与冠心病风险的关联

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
PubMed 文献 · JAMA · 2019-01-01
一句话结论在ApoB每降低10 mg/dL时,LPL变异与LDLR变异与相似的冠心病风险降低相关(OR 0.771 vs 0.773),提示降脂临床获益可能与ApoB绝对变化成比例。

该研究采用孟德尔随机化分析,纳入北美或欧洲63项队列或病例对照研究的654 783名参与者(其中91 129例冠心病),比较甘油三酯降低型LPL基因变异与LDL-C降低型LDLR基因变异与冠心病风险的关联。结果显示,ApoB每降低10 mg/dL,LPL评分与LDLR评分与相似的冠心病风险降低相关(OR 0.771 vs 0.773)。多变量孟德尔随机化分析中,校正ApoB差异后,甘油三酯与LDL-C水平与冠心病风险的关联变为无效。作者认为,降低甘油三酯和LDL-C的临床获益可能与ApoB的绝对变化成比例。

要点

  • ApoB每降低10 mg/dL,LPL评分与LDLR评分与相似的冠心病风险降低相关(OR 0.771 [95%CI 0.741-0.802] vs OR 0.773 [95%CI 0.747-0.801])。
  • LPL评分在ApoB每降低10 mg/dL时与甘油三酯降低69.9 mg/dL(95%CI 68.1-71.6)及LDL-C升高0.7 mg/dL(95%CI 0.03-1.4)相关。
  • LDLR评分在ApoB每降低10 mg/dL时与LDL-C降低14.2 mg/dL(95%CI 13.6-14.8)及甘油三酯降低1.9 mg/dL(95%CI 0.1-3.9)相关。
  • 多变量孟德尔随机化分析校正ApoB差异后,甘油三酯(OR 1.014 [95%CI 0.965-1.065],P=.19)与LDL-C(OR 1.010 [95%CI 0.967-1.055],P=.19)与冠心病风险的关联变为无效。
  • 作者认为,降低甘油三酯和LDL-C的临床获益可能与ApoB的绝对变化成比例。

适用人群与场景

  • 纳入1948年至2017年在北美或欧洲开展的63项队列或病例对照研究的参与者,共654 783人,其中91 129例冠心病,平均年龄62.7岁,51.4%为女性。

研究设计与关键结果

  • 研究类型为孟德尔随机化分析,纳入63项队列或病例对照研究,共654 783名参与者(91 129例冠心病),平均年龄62.7岁,51.4%为女性。
  • ApoB每降低10 mg/dL,LPL评分与甘油三酯降低69.9 mg/dL(95%CI 68.1-71.6;P=7.1×10⁻¹³⁶³)及LDL-C升高0.7 mg/dL(95%CI 0.03-1.4;P=.04)相关。
  • ApoB每降低10 mg/dL,LDLR评分与LDL-C降低14.2 mg/dL(95%CI 13.6-14.8;P=1.4×10⁻⁴⁶⁵)及甘油三酯降低1.9 mg/dL(95%CI 0.1-3.9;P=.04)相关。
  • ApoB每降低10 mg/dL,LPL评分与LDLR评分与相似的冠心病风险降低相关(OR 0.771 [95%CI 0.741-0.802],P=3.9×10⁻³⁸ vs OR 0.773 [95%CI 0.747-0.801],P=1.1×10⁻⁴⁶)。
  • 多变量孟德尔随机化分析校正ApoB差异后,甘油三酯与冠心病风险的关联为OR 1.014(95%CI 0.965-1.065,P=.19),LDL-C为OR 1.010(95%CI 0.967-1.055,P=.19),ApoB为OR 0.761(95%CI 0.723-0.798,P=7.51×10⁻²⁰)。

证据类型、等级与局限

  • 证据类型为孟德尔随机化分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,降低甘油三酯和LDL-C的临床获益可能与ApoB的绝对变化成比例。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Triglycerides and cholesterol are both carried in plasma by apolipoprotein B (ApoB)-containing lipoprotein particles. It is unknown whether lowering plasma triglyceride levels reduces the risk of cardiovascular events to the same extent as lowering low-density lipoprotein cholesterol (LDL-C) levels.

OBJECTIVE: To compare the association of triglyceride-lowering variants in the lipoprotein lipase (LPL) gene and LDL-C-lowering variants in the LDL receptor gene (LDLR) with the risk of cardiovascular disease per unit change in ApoB.

DESIGN, SETTING, AND PARTICIPANTS: Mendelian randomization analyses evaluating the associations of genetic scores composed of triglyceride-lowering variants in the LPL gene and LDL-C-lowering variants in the LDLR gene, respectively, with the risk of cardiovascular events among participants enrolled in 63 cohort or case-control studies conducted in North America or Europe between 1948 and 2017.

EXPOSURES: Differences in plasma triglyceride, LDL-C, and ApoB levels associated with the LPL and LDLR genetic scores.

MAIN OUTCOMES AND MEASURES: Odds ratio (OR) for coronary heart disease (CHD)-defined as coronary death, myocardial infarction, or coronary revascularization-per 10-mg/dL lower concentration of ApoB-containing lipoproteins.

RESULTS: A total of 654 783 participants, including 91 129 cases of CHD, were included (mean age, 62.7 years; 51.4% women). For each 10-mg/dL lower level of ApoB-containing lipoproteins, the LPL score was associated with 69.9-mg/dL (95% CI, 68.1-71.6; P = 7.1 × 10-1363) lower triglyceride levels and 0.7-mg/dL (95% CI, 0.03-1.4; P = .04) higher LDL-C levels; while the LDLR score was associated with 14.2-mg/dL (95% CI, 13.6-14.8; P = 1.4 × 10-465) lower LDL-C and 1.9-mg/dL (95% CI, 0.1-3.9; P = .04) lower triglyceride levels. Despite these differences in associated lipid levels, the LPL and LDLR scores were associated with similar lower risk of CHD per 10-mg/dL lower level of ApoB-containing lipoproteins (OR, 0.771 [95% CI, 0.741-0.802], P = 3.9 × 10-38 and OR, 0.773 [95% CI, 0.747-0.801], P = 1.1 × 10-46, respectively). In multivariable mendelian randomization analyses, the associations between triglyceride and LDL-C levels with the risk of CHD became null after adjusting for differences in ApoB (triglycerides: OR, 1.014 [95% CI, 0.965-1.065], P = .19; LDL-C: OR, 1.010 [95% CI, 0.967-1.055], P = .19; ApoB: OR, 0.761 [95% CI, 0.723-0.798], P = 7.51 × 10-20).

CONCLUSIONS AND RELEVANCE: Triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants were associated with similar lower risk of CHD per unit difference in ApoB. Therefore, the clinical benefit of lowering triglyceride and LDL-C levels may be proportional to the absolute change in ApoB.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Ference BA, Kastelein JJP, Ray KK, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019. PMID: 30694319. doi:10.1001/jama.2018.20045

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。